Can one infusion speed recovery from sickle cell lung crisis?
NCT ID NCT06818266
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a single dose of tocilizumab, an anti-inflammatory drug, can help children and adults with sickle cell disease recover faster from acute chest syndrome—a serious lung condition. Participants receive either the drug or a placebo, and researchers measure how quickly they can stop needing oxygen or breathing support. The trial aims to enroll 130 people aged 2 and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that reduces inflammation)
What this could lead to
If it works, this could provide a new treatment to help sickle cell patients recover faster from acute chest syndrome, a serious lung complication.
What could go wrong
This is a Phase 3 trial, but it is still early to know if tocilizumab will work better than standard care. There are risks like infections or allergic reactions from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of General Pediatrics and Sickle Cell Center, Necker-Enfants malades Hospital
RECRUITINGParis, 75015, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact